Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal DiseasesThe collaboration with Numab Therapeutics expands Boehringer Ingelheim ’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA)Numab ’s proprietary platform enables the engineering of first-in-class and best-in-class bi- and multi-specific antibodies in a true plug-and-play fashion
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news